Sign In
Buy CBAY
$32.48
+0 (+0%)
At Close: Apr 11, 2024
Cymabay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q1 2021 Results - Earnings Call Transcript
11:00pm, Thursday, 13'th May 2021
Cymabay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q1 2021 Results - Earnings Call Transcript
CymaBay Reports First Quarter 2021 Financial Results and Provides Corporate Update
04:06pm, Thursday, 13'th May 2021
Highly experienced executives, Dr. Dennis Kim as Chief Medical Officer and Lewis Stuart as Chief Commercial Officer, strengthen the management team
Cymabay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q4 2020 Results - Earnings Call Transcript
01:18am, Friday, 26'th Mar 2021
Cymabay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q4 2020 Results - Earnings Call Transcript
CymaBay Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Update
04:10pm, Thursday, 25'th Mar 2021
Actively recruiting patients in two global, clinical studies evaluating seladelpar in primary biliary cholangitis (PBC):
CymaBay Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 25, 2021
08:00am, Friday, 12'th Mar 2021
NEWARK, Calif., March 12, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic dis
5 Disruptive Biotech Stocks With Solid Long-Term Potential
10:41am, Monday, 04'th Jan 2021
Here we discuss five biotech stocks - EDIT, VRTX, NTLA, CBAY, MRNS - that could prove to be great investments in the long run.
NEWARK, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients
CymaBay Therapeutics to Present at Upcoming Investor Conferences
08:00am, Wednesday, 11'th Nov 2020
NEWARK, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic dise
CymaBay Is Clawing Back, Now We Just Need Pipeline Conversion
04:11pm, Sunday, 08'th Nov 2020
The FDA lifted all holds on all CymaBay liver disease studies back in July, since, shares have begun clawing back, +319% upside YTD. The company has presented positive top-line data from the ENHANCE s
CymaBay Therapeutics (CBAY) CEO Sujal Shah on Q3 2020 Results - Earnings Call Transcript
12:22pm, Saturday, 07'th Nov 2020
CymaBay Therapeutics (CBAY) CEO Sujal Shah on Q3 2020 Results - Earnings Call Transcript
CymaBay Announces Study to Evaluate the Potential for GPR119 Agonists to Prevent Hypoglycemia in Type 1 Diabetes
08:00am, Thursday, 05'th Nov 2020
The AdventHealth Translational Research Institute (TRI) in Orlando, FL to lead the study, funded by the Helmsley Charitable Trust, evaluating MBX-2982, a GPR119 agonist, for its ability to increase se
CymaBay Therapeutics to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020
04:32pm, Friday, 30'th Oct 2020
NEWARK, Calif., Oct. 30, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic dise
IPO Update: Metacrine Seeks $85 Million U.S. IPO
02:58pm, Friday, 11'th Sep 2020
Metacrine has filed to raise $85 million in an IPO of its common stock. The firm is developing treatments for NASH, a liver disease whose prevalence is increasing rapidly.
Viking Therapeutics: Another Year In Review
02:39pm, Thursday, 13'th Aug 2020
Recently announced Q2'20 financial results and provided key updates on development timelines. Filed IND for VK0214 in X-ALD.
CymaBay Therapeutics Inc. (CBAY) Q2 2020 Earnings Call Transcript
07:01am, Tuesday, 11'th Aug 2020
Joining me on the call today are Sujal Shah, chief executive officer; Dr. Sujal will provide an update on recent progress and plans on the development program for seladelpar, as well as a brief summa
